TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Tislelizumab is now approved in nine indications in China
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Subscribe To Our Newsletter & Stay Updated
